GLP-1 medications can do more than lower blood glucose in type 2 diabetes they can also benefit the heart, kidneys, liver, and overall metabolic health
Market projections suggest that the GLP-1 drug market will will almost double to USD 135 bn in the next five years as the number of GLP-1 users triple from almost 40 million to 120 million worldwide
Laboratory Testing and Monitoring: In any rigorous scientific study, monitoring metabolic biomarkers is essential
GLP-1R action on brown adipose tissue (BAT) thermogenesis In addition to causing changes in feeding, central GLP-1R activation may regulate body weight by increasing brown adipose tissue (BAT) thermogenesis (reviewed in Lockie et al., 2013)
Pills eliminate the need for refrigeration and injection supplies, but pricing and insurance coverage will remain critical factors
The safety of microdosing semaglutide (the active ingredient in Ozempic and Wegovy) remains a subject of debate